TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03025555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bre.flex
Description: Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
Study: NCT04678713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: investigate the nutritional determinants of MFO in moderate to well-train individuals
Description: The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: investigate the nutritional determinants of MFO in moderate to well-train individuals
Description: The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate the physiological determinants of MFO in moderate to well-train individuals
Description: Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate the physiological determinants of MFO in moderate to well-train individuals
Description: Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
Study: NCT03404050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and dance movement therapy
Description: Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
Study: NCT00039117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03022578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermal Therapy
Description: Undergo LITT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO
Study: NCT03245762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 4 IU/day of oxytocin administered via nasal spray device each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 IU/day of placebo administered via nasal spray device each morning
Study: NCT03347266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injections
Description: •VVZ-149 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study: NCT03765515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twinfix Ti
Description: The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-Fix
Description: Q-Fix
Study: NCT02762292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of work of breathing using indirect calorimeter
Description: 1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients.
Study: NCT02716688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
Study: NCT04016350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training with Inulin Propionate Ester
Description: Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training with placebo
Description: Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
Study: NCT02306083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucosamine sulfate 1500 mg three times a day
Study: NCT03676478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed start enteral support @ POD5
Description: instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7.
Study: NCT03294941

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: HepQuant SHUNT Liver Diagnostic Kit
Description: Serial testing over 48 weeks
Study: NCT00787683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-monitoring provided by LUMAX ICD device and CardioMessenger II
Description: All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
Study: NCT02943707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells infusion
Description: Autologous bone marrow stem cells are infused into proper hepatic artery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drugs such as Ursodeoxycholic Acid tablets
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drugs such as Ursodeoxycholic Acid tablets
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
Study: NCT00702650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: 30 mg to 120 mg administered topically once daily for 120 days
Study: NCT03408223

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study: NCT02564406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR
Study: NCT02733575

Intervention type: OTHER
Group type: OTHER
Intervention: Compassion Focused Therapy
Description: Up to 26 sessions of Compassion Focused Therapy
Study: NCT01853696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loteprednol etabonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone acetate 1%
Study: NCT04296786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20mg po per week continuously
Study: NCT01084395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Safer Sex Intervention
Description: Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Safer Sex Communication Intervention
Description: Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.

Intervention type: OTHER
Group type: OTHER
Intervention: Adolescent Health Promotion Control Condition
Description: Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.

Intervention type: OTHER
Group type: OTHER
Intervention: Parent Health Promotion Control Condition
Description: Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
Study: NCT00986947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg and rituximab
Description: A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA).
Study: NCT02101749

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent inactivated influenza
Description: intradermal or intramuscular injection in the deltoid area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent inactivated influenza
Description: intradermal or intramuscular injection in the deltoid area.
Study: NCT03112733

Intervention type: DIAGNOSTIC_TEST
Intervention: TFF3, SFRP4, Romo1, NFKB
Description: Blood samples of all participants will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: TFF3, SFRP4, Romo1, NFKB
Description: Blood samples of all participants will be collected.
Study: NCT03398239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive mechanical ventilation
Study: NCT04459598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Single oral dose, 600-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose, 60 mg (2 x 30 mg) tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quizartinib
Description: Single oral dose, 60 mg (2 x 30 mg) tablets
Study: NCT03105921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Description: The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
Study: NCT02685072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mgs BID)
Description: Transdermal Nicotine Patch (TNP) + Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TNP + Placebo
Study: NCT02503254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHTP 1.0
Description: CHTP 1.0 ad libitum for 5 days in confinement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study: NCT02144636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: herbalife protein shake
Study: NCT02608008

Intervention type: DEVICE
Intervention: Data analysis
Description: data parameters Analysis

Intervention type: DEVICE
Intervention: Data analysis
Description: data parameters Analysis

Intervention type: DEVICE
Intervention: Data analysis
Description: data parameters Analysis

Intervention type: DEVICE
Intervention: Data analysis
Description: data parameters Analysis
Study: NCT03623295

Intervention type: OTHER
Intervention: Blood sample
Description: Blood withdrawal.

Intervention type: OTHER
Intervention: Blood sample
Description: Blood withdrawal.

Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire about the bleeds that patients experienced in the past.

Intervention type: OTHER
Intervention: MRI-imaging
Description: MRI imaging of joints.

Intervention type: OTHER
Intervention: Physical examination
Description: Physical examination of joint status.
Study: NCT03865589

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Elastography
Description: Ultrasound shear wave elastography
Study: NCT04268628

Intervention type: OTHER
Intervention: Serum and plasma samples analysis
Description: This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
Study: NCT04148859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amnioreduction
Description: The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
Study: NCT05611996

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peers plus
Description: Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texting to older adults with depression.
Study: NCT02634905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual session therapeutic education
Description: within 2 weeks after inclusion (week 0)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Study: NCT03528057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostat
Description: Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
Study: NCT00772005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 150 mg/day armodafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day armodafinil
Study: NCT02290717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB therapy
Description: NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Cream 0.05%
Description: 4 times a week (standard IPD protocol)
Study: NCT04504318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG Oral Tablet
Description: Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
Study: NCT00772005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 250 mg/day armodafinil
Study: NCT02897388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk consume promotion
Description: (1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
Study: NCT04580537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enstilar
Description: Daily application on affected fingers (nail plates, nail folds, and surrounding skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Daily application on affected fingers (nail plates, nail folds, and surrounding skin)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser
Description: Pre-treatment of affected fingers (nail plates, nail folds)